ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Michael Gordon of Fenway still part of PMN?

<< Previous

Bullboard Posts

Next >>

Comment by BottomBrokeron Feb 10, 2022 9:09am

115 Views

Post# 34415913

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Michael Gordon of Fenway still part of PMN?

So you're saying PMN should respond directly on their website to the misinformation you dissemenated on an anoymous messageboard?

Maybe they reserve that space for more important information, like, you know, their alzheimer research?

Anyway, let's refocus our attention to PMN and forget about false investor reports, duplicate accounts, lawsuits and the second shooter on the grassy knoll.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario